100+ Free Arab Board Oncology Clinical Practice Questions

Prepare for the Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Arab Board Specialty Certification Exams

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Sample Arab Board Oncology Clinical Practice Questions

Try these sample questions to test your Arab Board Oncology Clinical exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 52-year-old postmenopausal woman undergoes lumpectomy and sentinel lymph node biopsy for a 2.1 cm invasive ductal carcinoma. Pathology reveals grade 2 carcinoma, ER 95%, PR 80%, HER2-negative (IHC 0), and 1 sentinel lymph node containing a 1.2 mm micrometastasis (pN1mi). Genomic profiling reveals a 21-gene Recurrence Score (RS) of 14. What is the most appropriate adjuvant systemic therapy?

A.Adjuvant endocrine therapy alone with an aromatase inhibitor

B.Adjuvant dose-dense AC followed by paclitaxel plus endocrine therapy

C.Adjuvant TC (docetaxel and cyclophosphamide) plus endocrine therapy

D.Adjuvant ovarian function suppression plus tamoxifen

Explanation: Based on the landmark RxPONDER trial, postmenopausal women with hormone receptor-positive, HER2-negative breast cancer and 1-3 positive lymph nodes with a 21-gene Recurrence Score of 25 or lower derive no significant disease-free or overall survival benefit from the addition of adjuvant chemotherapy to endocrine therapy. Standard adjuvant therapy is an aromatase inhibitor (e.g., letrozole or anastrozole) for 5 to 10 years. In contrast, premenopausal women in RxPONDER did demonstrate a benefit from chemotherapy regardless of low RS.

2A 45-year-old premenopausal woman with clinical stage IIA (cT2N0M0) HER2-positive (IHC 3+), ER-negative breast cancer completes 6 cycles of neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab). She undergoes breast-conserving surgery, and final surgical pathology reveals a 1.2 cm residual invasive carcinoma in the breast with negative margins and clear lymph nodes (ypT1c ypN0). What is the preferred adjuvant HER2-targeted therapy?

A.Trastuzumab emtansine (T-DM1) for 14 cycles

B.Trastuzumab plus pertuzumab to complete 1 full year

C.Trastuzumab monotherapy to complete 1 full year

D.Trastuzumab deruxtecan (T-DXd) for 8 cycles

Explanation: In the KATHERINE phase III trial, patients with HER2-positive early breast cancer who had residual invasive disease (non-pCR) after neoadjuvant taxane and trastuzumab-based chemotherapy had a 50% reduction in the risk of recurrence or death with adjuvant T-DM1 compared to continuing trastuzumab. Adjuvant T-DM1 is administered every 3 weeks for a total of 14 cycles. Continuing dual HER2 blockade or single-agent trastuzumab is reserved for patients achieving a pathologic complete response (pCR).

3A 38-year-old woman presents with a 3.5 cm palpable mass in the left breast and ipsilateral mobile axillary lymphadenopathy. Core biopsy confirms grade 3 invasive ductal carcinoma, ER 0%, PR 0%, HER2-negative (triple-negative breast cancer). Staging CT and bone scan show no distant metastases (cT2N1M0). What is the standard neoadjuvant systemic therapy regimen?

A.Pembrolizumab combined with carboplatin and paclitaxel, followed by pembrolizumab with doxorubicin and cyclophosphamide

B.Dose-dense AC followed by weekly paclitaxel without immunotherapy

C.Docetaxel plus cyclophosphamide (TC) for 6 cycles

D.Cisplatin plus gemcitabine for 4 cycles

Explanation: The KEYNOTE-522 trial established neoadjuvant pembrolizumab plus platinum-containing chemotherapy (carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide) followed by adjuvant pembrolizumab as the standard of care for high-risk early-stage triple-negative breast cancer (stage II-III). This regimen significantly increased the pathologic complete response rate and event-free survival regardless of PD-L1 expression. Omitting immunotherapy or platinum results in inferior long-term outcomes.

4A 60-year-old postmenopausal woman presents with newly diagnosed de novo metastatic invasive ductal carcinoma of the breast with multiple asymptomatic osteolytic bone metastases and two small asymptomatic liver lesions. Biopsy confirms ER 90%, PR 70%, and HER2 IHC 1+ (HER2-negative). She has no visceral crisis and an ECOG performance status of 1. What is the preferred first-line systemic therapy?

A.An aromatase inhibitor (e.g., letrozole) plus a CDK4/6 inhibitor (e.g., ribociclib, abemaciclib, or palbociclib)

B.Single-agent chemotherapy with capecitabine

C.Combination chemotherapy with doxorubicin and cyclophosphamide (AC)

D.Tamoxifen monotherapy

Explanation: International consensus guidelines (ESMO, ASCO, NCCN) recommend a non-steroidal aromatase inhibitor (or fulvestrant) combined with a CDK4/6 inhibitor (ribociclib, abemaciclib, or palbociclib) as the preferred first-line therapy for postmenopausal women with HR-positive, HER2-negative metastatic breast cancer without impending visceral crisis. Multiple phase III trials (MONALEESA, MONARCH, PALOMA) have demonstrated substantial progression-free survival benefits, with several showing significant overall survival prolongation. Cytotoxic chemotherapy is reserved for life-threatening visceral crisis or endocrine refractoriness.

5A 56-year-old woman with metastatic ER-positive, HER2-negative breast cancer experiences disease progression after 24 months on first-line letrozole plus palbociclib. Circulating tumor DNA (ctDNA) next-generation sequencing identifies an activating ESR1 mutation (Y537S). The tumor is PIK3CA wild-type and BRCA1/2 wild-type. What is the most appropriate next-line targeted endocrine therapy?

A.Elacestrant oral monotherapy

B.Alpelisib plus fulvestrant

C.Olaparib monotherapy

D.Re-challenge with letrozole plus anastrozole

Explanation: Elacestrant is an oral selective estrogen receptor degrader (SERD) that demonstrated statistically significant improvement in progression-free survival over standard-of-care endocrine monotherapy in the EMERALD phase III trial, with the greatest benefit observed in patients harboring activating ESR1 mutations who had prior CDK4/6 inhibitor therapy. Activating ESR1 mutations confer resistance to aromatase inhibitors by rendering the estrogen receptor constitutively active in the absence of ligand.

6A 48-year-old premenopausal woman completes modified radical mastectomy for a 4.5 cm invasive ductal carcinoma. Final pathology confirms ER 90%, PR 85%, HER2-negative, grade 3, with 5 of 14 positive axillary lymph nodes (pT2N2aM0). She completes adjuvant dose-dense AC-paclitaxel chemotherapy and post-mastectomy radiation therapy. In addition to ovarian function suppression and an aromatase inhibitor, which adjuvant targeted agent is indicated to reduce recurrence risk?

A.Abemaciclib for 2 years

B.Palbociclib for 1 year

C.Trastuzumab for 1 year

D.Everolimus for 2 years

Explanation: In the monarchE phase III trial, adding the oral CDK4/6 inhibitor abemaciclib (150 mg twice daily for 2 years) to standard adjuvant endocrine therapy significantly improved invasive disease-free survival and distant relapse-free survival in patients with high-risk, node-positive, HR-positive, HER2-negative early breast cancer (defined as >=4 positive nodes, or 1-3 positive nodes with grade 3 disease or tumor size >=5 cm). Other CDK4/6 inhibitors like palbociclib failed to demonstrate adjuvant benefit in trials (PALLAS, PENELOPE-B).

7A 50-year-old woman undergoes left modified radical mastectomy for a 5.5 cm invasive lobular carcinoma with 5 positive axillary lymph nodes and extracapsular nodal extension (pT3N2aM0). Regarding post-mastectomy radiation therapy (PMRT), which target volumes must be irradiated according to ESTRO and ASTRO consensus guidelines?

A.Left chest wall, supraclavicular fossa, infraclavicular fossa, and internal mammary chain lymph nodes

B.Left chest wall alone

C.Left chest wall and axillary levels I and II alone

D.Supraclavicular fossa alone without chest wall irradiation

Explanation: Post-mastectomy radiation therapy (PMRT) is strongly indicated for patients with T3/T4 tumors or >=4 positive axillary lymph nodes. Comprehensive regional nodal irradiation (RNI) includes the supraclavicular/infraclavicular fossa, internal mammary lymph node chain, and the chest wall. Landmark trials (MA.20, EORTC 22922) and consensus guidelines confirm that comprehensive regional nodal irradiation significantly reduces locoregional recurrence, distant metastasis, and breast cancer mortality in node-positive disease.

8A 34-year-old woman with a known deleterious germline BRCA1 mutation completes neoadjuvant anthracycline/taxane/carboplatin chemotherapy for triple-negative breast cancer (cT2N1M0). At definitive surgery, pathology reveals 1.8 cm of residual invasive carcinoma with 2 positive axillary nodes (ypT1c ypN1a). Which adjuvant targeted therapy is proven to significantly improve invasive disease-free survival and overall survival?

A.Olaparib orally for 1 year

B.Bevacizumab intravenously for 1 year

C.Capecitabine monotherapy for 6 months as the sole systemic option

D.Trastuzumab emtansine for 14 cycles

Explanation: In the OlympiA phase III trial, 1 year of adjuvant olaparib (a PARP inhibitor) significantly improved 3-year invasive disease-free survival (85.9% vs 77.1%) and overall survival in patients with germline BRCA1 or BRCA2 mutations and high-risk HER2-negative early breast cancer who had residual disease after neoadjuvant chemotherapy. Olaparib exploits synthetic lethality in tumors deficient in homologous recombination DNA repair.

9A 58-year-old woman with metastatic HER2-positive breast cancer experiences systemic disease progression in the lungs and liver while receiving maintenance trastuzumab and pertuzumab following first-line docetaxel, trastuzumab, and pertuzumab (CLEOPATRA regimen). Brain MRI shows no intracranial metastases. What is the preferred second-line systemic therapy?

A.Trastuzumab deruxtecan (T-DXd)

B.Lapatinib plus capecitabine

C.Trastuzumab plus vinorelbine

D.Eribulin monotherapy

Explanation: In the DESTINY-Breast03 phase III trial, trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate comprising an anti-HER2 antibody linked to a topoisomerase I inhibitor payload, demonstrated remarkable superiority over T-DM1 in second-line HER2-positive metastatic breast cancer, with a 72% reduction in the risk of disease progression or death and significant overall survival benefit. T-DXd is the definitive second-line standard of care.

10A 44-year-old woman with metastatic HER2-positive breast cancer previously treated with trastuzumab, pertuzumab, and T-DM1 develops active, progressive, multiple brain metastases (largest 1.5 cm) without mass effect or neurological deficit. Systemic disease is stable. Which systemic regimen has demonstrated proven intracranial and systemic overall survival benefit in this setting?

A.Tucatinib plus capecitabine plus trastuzumab

B.Trastuzumab plus docetaxel

C.Endocrine therapy plus palbociclib

D.Everolimus plus exemestane

Explanation: The HER2CLIMB trial demonstrated that adding tucatinib, a highly selective HER2 tyrosine kinase inhibitor that crosses the blood-brain barrier, to capecitabine and trastuzumab significantly improved progression-free survival, intracranial progression-free survival, and overall survival in patients with HER2-positive metastatic breast cancer, including those with active and progressive brain metastases.

About the Arab Board Oncology Clinical Exam

The Arab Board Oncology Final Clinical and Oral Examination is the definitive exit qualification awarded by the Arab Board of Health Specializations (ABHS) Scientific Council of Oncology. Conducted across accredited training centres in Arab League member states, this high-stakes examination evaluates senior oncology fellows on multidisciplinary cancer care, evidence-based systemic therapy selection, radiotherapy treatment planning and contouring, management of acute oncologic emergencies, and complex palliative communication. Candidates are examined through structured clinical cases, imaging and radiotherapy planning reviews, and direct oral viva voce with expert examiners.

Assessment

A multi-station structured clinical and oral exit examination (OSCE/viva format) assessing real-time multidisciplinary cancer management, diagnostic workup, systemic therapy regimens, radiotherapy simulation and target volume contouring, oncologic emergencies, and palliative symptom control.

Time Limit

Approximately 2 to 3 hours

Passing Score

Set by the Arab Board Scientific Council of Oncology, generally around 60% aggregate score across all clinical and oral stations.

Exam Fee

Set by ABHS and national councils (Arab Board of Health Specializations (ABHS))

Arab Board Oncology Clinical Exam Content Outline

12%

Breast Oncology

Early and advanced breast cancer, molecular subtypes, neoadjuvant and adjuvant systemic therapy, post-mastectomy radiation therapy, and CDK4/6 inhibitor management.

12%

Thoracic Oncology

Non-small cell lung cancer (targeted therapies, immunotherapy, SBRT, concurrent chemoradiation), small cell lung cancer, mesothelioma, and thymic neoplasms.

16%

Gastrointestinal Oncology

Esophageal, gastric, pancreatic, hepatobiliary, colorectal (TNT, MSI-H, targeted therapy), anal canal SCC, and GIST multidisciplinary management.

12%

Genitourinary Oncology

Prostate cancer (risk stratification, definitive RT, mHSPC/mCRPC therapy), renal cell carcinoma, urothelial carcinoma (EV-pembro, neoadjuvant chemo), and germ cell tumors.

10%

Gynecologic Oncology

Cervical cancer (chemoradiotherapy with IGABT), endometrial cancer (molecular classification, adjuvant RT/chemo), epithelial ovarian cancer, and GTN.

10%

Hematologic Malignancies and Lymphomas

Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell and follicular lymphoma, multiple myeloma, acute leukemias, and tumor lysis syndrome.

10%

Head, Neck, and CNS Oncology

HPV-associated oropharyngeal SCC, nasopharyngeal carcinoma, definitive and adjuvant chemoradiation contouring, glioblastoma (Stupp protocol), and brain metastases SRS.

Oncologic Emergencies and Acute Toxicity

Malignant spinal cord compression, hypercalcemia of malignancy, febrile neutropenia, SVC syndrome, immune-related adverse events, and extravasation.

10%

Palliative Care and Radiation Principles

Cancer pain management, palliative bone/brain RT, malignant bowel obstruction, radiation physics (CTV/PTV, OAR constraints, BED), and geriatric oncology.

How to Pass the Arab Board Oncology Clinical Exam

What You Need to Know

Passing score: Set by the Arab Board Scientific Council of Oncology, generally around 60% aggregate score across all clinical and oral stations.
Assessment: A multi-station structured clinical and oral exit examination (OSCE/viva format) assessing real-time multidisciplinary cancer management, diagnostic workup, systemic therapy regimens, radiotherapy simulation and target volume contouring, oncologic emergencies, and palliative symptom control.
Time limit: Approximately 2 to 3 hours
Exam fee: Set by ABHS and national councils

Keys to Passing

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Arab Board Oncology Clinical Study Tips from Top Performers

1Structure your clinical case answers using a multidisciplinary tumor board (MDT) framework: baseline staging workup, biomarker testing, multimodal sequencing (surgery, systemic therapy, RT), and monitoring for toxicities.

2Master standard radiation therapy dose-fractionation schedules and organ-at-risk (OAR) tolerance constraints (e.g., spinal cord, brainstem, optic chiasm, lungs, heart, bowel, rectum, femoral heads).

3Stay strictly current on molecular-targeted and immune checkpoint therapies across solid tumors and hematologic malignancies, including actionable driver mutations and immune-related adverse event management algorithms.

Frequently Asked Questions

What is the structure of the Arab Board Oncology Final Clinical and Oral Examination?

The examination is conducted as a multi-station clinical OSCE and structured oral viva voce. Candidates rotate through stations evaluating clinical vignette interpretation, real-time radiotherapy target volume and organ-at-risk contouring review, systemic chemotherapy/immunotherapy regimen design, oncologic emergency response, and palliative case management.

What passing score is required to pass the ABHS Oncology Clinical Exam?

The passing standard is established by the ABHS Scientific Council of Oncology using criterion-referenced standard-setting methods, generally requiring an aggregate score of approximately 60% with minimum competence demonstrated across clinical case and oral stations.

How should oncology fellows prepare for the clinical and oral viva stations?

Preparation requires reviewing landmark clinical trials (e.g., KEYNOTE, CheckMate, DESTINY, PACIFIC, PRODIGE, STAMPEDE), mastering radiation contouring consensus guidelines (ESTRO/RTOG/ASTRO), memorizing systemic therapy regimens and toxicities, and practicing structured oral case delivery.

Are these practice questions identical to the official ABHS examination?

No. This practice bank is an independent English-language educational adaptation designed by oncology educators to mirror the clinical decision-making, multidisciplinary case scenarios, and evidence-based standards tested on the Arab Board Oncology Final Clinical and Oral Examination.

100+ Free Arab Board Oncology Clinical Practice Questions

Explore More Arab Board Specialty Certification Exams

Arab Board Pediatrics Part 1 Written Exam (ABHS)

Arab Board Anatomic Pathology Part 1 Written Exam (ABHS)

Arab Board Anesthesia and Intensive Care Final Clinical and Oral Exam (ABHS)

Arab Board Anesthesia and Intensive Care Final Written Exam (ABHS)

Arab Board Anesthesia Part 1 Written Exam (ABHS)

Arab Board Clinical Pathology Part 1 Written Exam (ABHS)